I think the market's reply to this PR should tell the company something about it's effectiveness, it doesn't work.
I'm not saying what the company's doing doesn't work, I'm saying they need to present more data about how well its therapies are working. Motherhood and apple pie go only so far.
I'd certainly be eager to see data on any, or all, of the diseases that GMED is working with, I believe they would be impressive, however, data presented to me means nothing, what's important is presenting it in an appropriate technical forum, then you can talk about it with investors.
It seems to me that some of the drugs they're working with are from drug families that could have some serious health issues. I'd like to see them discuss what the FDA's doing in getting approved drugs back off the market. There is little doubt in my mind that some approved drugs are doing harm to some people, I know someone who had heart problems and was on Vioxx, he told me how much better his arthritis was. The point I'm trying to make is, there may be proper applications for these drugs, GMED might want to study that. It's clear that they're not good for prolongued applications, but they might be the perfect drug for short term applications.
I'm not saying that Dr. Moskowitz is the answer to all the drugmakers problems, he isn't, but he finds ways to use drugs that they haven't thought of. Furthermore, I believe he's honest about problems that he encounters. Many drugs do miraculous things given properly and are deadly given improperly. Vioxx may have proper usages, but the unwillingness to admit it had problems may result in the proper uses never being found.
I hope that in the near future Dr. Moskowitz can get proper credit for what he's trying to do. PR's like todays aren't the right way to do it, IMHO.
Gary |
